Citi reiterates its Neutral rating on pharmaceutical company Novo Nordisk with a price target of DKK 310.
The capital markets day gave the bank little reason to change its cautious view.
The growth ambition for 2026-2030 is in line with consensus, while the outlook for largely stable margins is weaker.
Wegovy Pill and Cagrisema may offset price pressure on GLP-1, but Citi emphasizes that execution will be decisive.
